ALLERGY THERAPEUTICS PLC (AGY) — Interim Results 2022

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Allergy Therapeutics PLC interim results investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted anytime by the q and a tab situated on the right hand corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company will review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Manuel, CEO. Good morning. Okay. Thank you. Thank you very much, Alessandro, and good morning, everybody. Thank you for joining us. And here, we have the presentation team. Joining me is Nick Wyman, chief financial officer, and Alan Bolimir, head of business innovation. I'm CEO, of the company, Manuel Lobet, of AGY Therapeutics, and we are here to present, the half year results, of the fiscal year, and the six months ending in on 12/31/2021. This is a pivotal year because we are, running two very important clinical trials, one phase three trial for grass allergic patients and one, phase one trial for peanut allergic patients. But before getting into details, we are showing here the typical disclaimer slide for compliant purposes. And then we have here a snapshot of bullet points about our company. We are a fully integrated biopharmaceutical company based in The UK. We are a leading provider of subcutaneous, aluminum free vaccines. We provide treatments that have the potential to cure the disease, not just the symptoms. In fact, we cure most of the cases allergic rhinitis. We are focused on severe patients. We became a com...